Global Stem Cells Group (GSCG) has signed a historic agreement with a company known as Bioscience Cell Factor- this Dubai-based healthcare company will allow GSCG to act as their representatives operating in both the Middle East and Latin America.
One of the world’s largest nongovernmental funders of science, the Wellcome Trust, is enlarging its focus to include goal-oriented, as well as basic research. The London-based philanthropy, which spends more than £1 billion per year, said today it will boost funding for research on infectious diseases, the health effects of global warming, and mental health.
Lineage Cell Therapeutics, Inc. and Cancer Research UK have announced encouraging preliminary results from an ongoing Phase I clinical study of VAC2 in non-small cell lung cancer (NSCLC). Produced from a pluripotent cell technology using a directed differentiation method, VAC2 has demonstrated remarkably potent induction of immune responses in all patients dosed to date.
Ezra announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence (AI), designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first Prostate AI to ever be cleared by the FDA.
Congratulations to Cherie Stabler, Ph.D., professor in the J. Crayton Pruitt Family Department of Biomedical Engineering, for receiving a $1.7 million RO1 grant from the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for her project, “Engineering Immunomodulatory Nanoscale Coatings for Protecting Islet Transplants.”
Agios Pharmaceuticals, Inc. announced the withdrawal of its European Marketing Authorization Application for TIBSOVO® for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.
Cyclo Therapeutics, Inc. received notification from the US FDA that enrollment could proceed for its Phase III global pivotal clinical trial, “A Phase III, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1”.
